These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37699634)
101. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study). Kong Y; Chen R; Xu M; Zhang J; Chen G; Hong Z; Zhang H; Dai X; Ma Y; Zhao X; Peng Y; Zhang C; Xing P; Zhang L BMJ Open; 2024 Mar; 14(3):e075642. PubMed ID: 38458816 [TBL] [Abstract][Full Text] [Related]
102. Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot. Beard C; Rogers CA; Fleming L; Conibear J; Evison M; Newsom-Davis T; Barwick T; Mills N; Stokes EA; De Sousa P; Batchelor T; Rawlinson J; Baos S; Harris R; Lim E BMJ Open; 2023 Dec; 13(12):e081650. PubMed ID: 38072470 [TBL] [Abstract][Full Text] [Related]
103. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. Wang S; Huang HY; Wu D; Fang H; Ying J; Bai Y; Yu Y; Fang Y; Jiang N; Sun C; Yu A; Fan Q; Xing S; Ni Y; Zhang W; Wu C; Ji X; Wang H; Guo Y; Tang Q; Wang Y; Tang Y; Li N BMJ Open; 2021 Jun; 11(6):e044543. PubMed ID: 34083331 [TBL] [Abstract][Full Text] [Related]
104. Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China. Yu J; Liu H; Wu Y BMJ Open; 2024 May; 14(5):e081090. PubMed ID: 38806431 [TBL] [Abstract][Full Text] [Related]
105. Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial. De Caluwé A; Buisseret L; Poortmans P; Van Gestel D; Salgado R; Sotiriou C; Larsimont D; Paesmans M; Craciun L; Stylianos D; Vandekerckhove C; Reyal F; Isabelle V; Eiger D; Piccart M; Romano E; Ignatiadis M BMC Cancer; 2021 Aug; 21(1):899. PubMed ID: 34362344 [TBL] [Abstract][Full Text] [Related]
106. Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial. Hudson EM; Noutch S; Webster J; Brown SR; Boele FW; Al-Salihi O; Baines H; Bulbeck H; Currie S; Fernandez S; Hughes J; Lilley J; Smith A; Parbutt C; Slevin F; Short S; Sebag-Montefiore D; Murray L BMJ Open; 2024 Mar; 14(3):e078926. PubMed ID: 38458809 [TBL] [Abstract][Full Text] [Related]
107. China special issue on gastrointestinal tumors-Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD-1 blockade: A post hoc analysis of the PICC phase II trial. Cao W; Hu H; Li J; Wu Q; Shi L; Li B; Zhou J; Wang X; Chen J; Wang C; Wang H; Deng W; Huang Y; Deng Y Int J Cancer; 2023 Dec; 153(11):1894-1903. PubMed ID: 37409565 [TBL] [Abstract][Full Text] [Related]
108. Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report. Lin Y; Chen Y; Lin S; Zheng J; Zhang X; Gan L J Immunother; 2024 Apr; 47(3):101-105. PubMed ID: 38037229 [TBL] [Abstract][Full Text] [Related]
109. New Opportunities for Minimizing Toxicity in Rectal Cancer Management. Couwenberg AM; Varvoglis DN; Grieb BC; Marijnen CAM; Ciombor KK; Guillem JG Am Soc Clin Oncol Educ Book; 2023 Jun; 43():e389558. PubMed ID: 37307515 [TBL] [Abstract][Full Text] [Related]
110. Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients. Wei J; Lu X; Liu Q; Li L; Liu S; Liu F; Fu Y; Fan X; Yang Y; Qi C; Yu Y; Guan W; Liu B Front Oncol; 2020; 10():554040. PubMed ID: 33634011 [TBL] [Abstract][Full Text] [Related]
111. Benefits of cardiac coherence combined with medical hypnosis on preoperative anxiety before cancer surgery: the COHEC II study trial protocol. Amraoui J; Bordenave L; Leclerc G; Salvignol G; Jarlier M; Fiess C; Philibert L; Fuzier R; Touraine C BMJ Open; 2023 Dec; 13(12):e072215. PubMed ID: 38086587 [TBL] [Abstract][Full Text] [Related]
112. Immune checkpoint status and oncogenic mutation profiling of rectal cancer after neoadjuvant chemotherapy (KSCC1301-A2). Miyashita Y; Oki E; Kamori T; Akagi Y; Mori S; Hattori N; Kobayashi K; Shimokawa M; Oda Y; Mori M Ann Gastroenterol Surg; 2024 Mar; 8(2):251-261. PubMed ID: 38455493 [TBL] [Abstract][Full Text] [Related]
113. A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer. Melissourgou-Syka L; Gillespie MA; O'Cathail SM; Sansom OJ; Steele CW; Roxburgh CSD J Immunother Precis Oncol; 2023 Nov; 6(4):187-197. PubMed ID: 38143952 [TBL] [Abstract][Full Text] [Related]
114. Neoadjuvant Treatment of Mismatch Repair-Deficient Colon Cancer - Clinically Meaningful? Cercek A N Engl J Med; 2024 Jun; 390(21):2024-2025. PubMed ID: 38838316 [No Abstract] [Full Text] [Related]
115. Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study). Zhang W; Tang Y; Wei L; Liu S; Wang W; Chi Y; Wang Y; Kang W; Huang W; Deng F; Li H; Ma H; Jiang L; Ding Z; Feng L; Li Y; Chen Y; Zhou H; Hu C; Jin J Colorectal Dis; 2024 Sep; 26(9):1732-1740. PubMed ID: 39020518 [TBL] [Abstract][Full Text] [Related]
116. Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C). Zhang H; Li Y; Xia F; Sun Y; Shen L; Wan J; Chen Y; Wang Y; Zhou M; Wu R; Zhou S; Wang Y; Liu F; Cai S; Zhang Z BMJ Open; 2024 Feb; 14(2):e079442. PubMed ID: 38309748 [TBL] [Abstract][Full Text] [Related]
117. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E). Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608 [TBL] [Abstract][Full Text] [Related]
118. Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. Teo MTW; McParland L; Appelt AL; Sebag-Montefiore D Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):146-158. PubMed ID: 29254769 [TBL] [Abstract][Full Text] [Related]
119. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial). Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634 [TBL] [Abstract][Full Text] [Related]